AI-10-49 is a selective small-molecule inhibitor primarily used in biochemical and pharmacological research. It targets specific signaling pathways involved in cancer cell proliferation, particularly those related to mutant forms of signaling proteins such as KRAS. By inhibiting downstream effectors in these pathways, AI-10-49 helps suppress tumor growth in preclinical models, making it a valuable tool for studying oncogenic signaling mechanisms. Its application extends to research on drug resistance in cancers, especially in non-small cell lung cancer and pancreatic cancer, where KRAS mutations are common. Scientists use AI-10-49 to probe the dependencies of cancer cells on specific protein interactions, aiding in the identification of new therapeutic targets. Due to its role in modulating intracellular signaling, AI-10-49 is also employed in studies exploring combination therapies, where it enhances the efficacy of other anticancer agents. While not used clinically, it serves as a critical research compound for validating pathway inhibition and guiding the development of future cancer treatments.